Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Adjuvant Treatment for High-Risk HCC Recurrence
NCT06762782Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 1-year cumulative recurrence-free patient percentage. Started Feb 2025; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06762782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762782.